-
Something wrong with this record ?
Developments in immunosuppression
O. Viklicky, J. Slatinska, M. Novotny, P. Hruba
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Everolimus therapeutic use MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Immunosuppression Therapy methods MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Transplant Recipients statistics & numerical data MeSH
- Randomized Controlled Trials as Topic MeSH
- Graft Rejection immunology prevention & control MeSH
- Kidney Transplantation methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
PURPOSE OF REVIEW: In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. RECENT FINDINGS: Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that lowTAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to standTAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. SUMMARY: Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity.
Department of Nephrology Transplant Center
Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026107
- 003
- CZ-PrNML
- 005
- 20211026133214.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOT.0000000000000844 $2 doi
- 035 __
- $a (PubMed)33332922
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Viklicky, Ondrej $u Department of Nephrology, Transplant Center $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 245 10
- $a Developments in immunosuppression / $c O. Viklicky, J. Slatinska, M. Novotny, P. Hruba
- 520 9_
- $a PURPOSE OF REVIEW: In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. RECENT FINDINGS: Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that lowTAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to standTAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. SUMMARY: Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity.
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a everolimus $x terapeutické užití $7 D000068338
- 650 _2
- $a rejekce štěpu $x imunologie $x prevence a kontrola $7 D006084
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresivní léčba $x metody $7 D007165
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a transplantace ledvin $x metody $7 D016030
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a příjemce transplantátu $x statistika a číselné údaje $7 D066027
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Slatinska, Janka $u Department of Nephrology, Transplant Center
- 700 1_
- $a Novotny, Marek $u Department of Nephrology, Transplant Center
- 700 1_
- $a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 773 0_
- $w MED00152752 $t Current opinion in organ transplantation $x 1531-7013 $g Roč. 26, č. 1 (2021), s. 91-96
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33332922 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133220 $b ABA008
- 999 __
- $a ok $b bmc $g 1714963 $s 1146614
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 26 $c 1 $d 91-96 $e 20210201 $i 1531-7013 $m Current opinion in organ transplantation $n Curr. Opin. Organ Transpl. $x MED00152752
- LZP __
- $a Pubmed-20211013
